Berenberg Bank Analysts Give Fresenius SE & Co KGaA (FRE) a €81.85 Price Target

Berenberg Bank set a €81.85 ($95.17) price objective on Fresenius SE & Co KGaA (FRA:FRE) in a research note released on Wednesday. The firm currently has a buy rating on the stock.

Other research analysts also recently issued research reports about the stock. Goldman Sachs Group set a €66.00 ($76.74) price target on shares of Fresenius SE & Co KGaA and gave the company a neutral rating in a report on Friday, August 24th. Warburg Research set a €80.00 ($93.02) price target on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a report on Tuesday, July 31st. DZ Bank restated a buy rating on shares of Fresenius SE & Co KGaA in a report on Tuesday, August 7th. Barclays set a €80.00 ($93.02) price target on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a report on Friday, August 24th. Finally, Commerzbank set a €79.00 ($91.86) price target on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a report on Tuesday, July 31st. One analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have issued a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of €76.44 ($88.89).

Fresenius SE & Co KGaA stock opened at €59.84 ($69.58) on Wednesday. Fresenius SE & Co KGaA has a 1-year low of €60.16 ($69.95) and a 1-year high of €80.00 ($93.02).

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Read More: Growth Stocks

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply